The biosimilar bevacizumab market is experiencing explosive growth, buoyed by rising global cancer rates and the urgent need for affordable oncology treatments. Bevacizumab, a monoclonal antibody marketed under the brand name Avastin, is a cornerstone of cancer therapy, inhibiting tumor blood vessel growth to slow progression in colorectal, lung, breast, and other cancers. As patents for the...